These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 38248857)

  • 41. Ultra-performance liquid chromatography coupled to mass spectrometry as a sensitive and powerful technology for metabolomic studies.
    Wang X; Sun H; Zhang A; Wang P; Han Y
    J Sep Sci; 2011 Dec; 34(24):3451-9. PubMed ID: 21826791
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human feces.
    Phua LC; Koh PK; Cheah PY; Ho HK; Chan EC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct; 937():103-13. PubMed ID: 24029555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive Two-Dimensional Gas Chromatography as a Bioanalytical Platform for Drug Discovery and Analysis.
    Zaid A; Hassan NH; Marriott PJ; Wong YF
    Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111606
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Solid phase microextraction coupled with comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry for high-resolution metabolite profiling in apples: implementation of structured separations for optimization of sample preparation procedure in complex samples.
    Risticevic S; DeEll JR; Pawliszyn J
    J Chromatogr A; 2012 Aug; 1251():208-218. PubMed ID: 22771060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mass spectrometric based approaches in urine metabolomics and biomarker discovery.
    Khamis MM; Adamko DJ; El-Aneed A
    Mass Spectrom Rev; 2017 Mar; 36(2):115-134. PubMed ID: 25881008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolomics toward personalized medicine.
    Jacob M; Lopata AL; Dasouki M; Abdel Rahman AM
    Mass Spectrom Rev; 2019 May; 38(3):221-238. PubMed ID: 29073341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Simultaneous metabolomics and lipidomics analysis based on novel heart-cutting two-dimensional liquid chromatography-mass spectrometry.
    Wang S; Zhou L; Wang Z; Shi X; Xu G
    Anal Chim Acta; 2017 May; 966():34-40. PubMed ID: 28372724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mass-spectrometry-based lipidomics.
    Hu T; Zhang JL
    J Sep Sci; 2018 Jan; 41(1):351-372. PubMed ID: 28859259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The application of ion mobility mass spectrometry to metabolomics.
    Zhang X; Quinn K; Cruickshank-Quinn C; Reisdorph R; Reisdorph N
    Curr Opin Chem Biol; 2018 Feb; 42():60-66. PubMed ID: 29161611
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LC-MS-based metabolomics in the clinical laboratory.
    Becker S; Kortz L; Helmschrodt C; Thiery J; Ceglarek U
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():68-75. PubMed ID: 22074957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Supercritical fluid chromatography coupled to mass spectrometry - A metabolomics perspective.
    Shulaev V; Isaac G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1092():499-505. PubMed ID: 30008306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges and emergent solutions for LC-MS/MS based untargeted metabolomics in diseases.
    Cui L; Lu H; Lee YH
    Mass Spectrom Rev; 2018 Nov; 37(6):772-792. PubMed ID: 29486047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of metabolomics in personalized medicine for diabetes.
    Chowdhury S; Faheem SM; Nawaz SS; Siddiqui K
    Per Med; 2021 Sep; 18(5):501-508. PubMed ID: 34406076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A critical appraisal of the role of metabolomics in breast cancer research and diagnostics.
    Gadwal A; Panigrahi P; Khokhar M; Sharma V; Setia P; Vishnoi JR; Elhence P; Purohit P
    Clin Chim Acta; 2024 Jul; 561():119836. PubMed ID: 38944408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enantioselectivity Effects in Clinical Metabolomics and Lipidomics.
    Oliveira RV; Simionato AVC; Cass QB
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current state-of-the-art of nontargeted metabolomics based on liquid chromatography-mass spectrometry with special emphasis in clinical applications.
    Yin P; Xu G
    J Chromatogr A; 2014 Dec; 1374():1-13. PubMed ID: 25444251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of recent developments in GC-MS approaches to metabolomics-based research.
    Beale DJ; Pinu FR; Kouremenos KA; Poojary MM; Narayana VK; Boughton BA; Kanojia K; Dayalan S; Jones OAH; Dias DA
    Metabolomics; 2018 Nov; 14(11):152. PubMed ID: 30830421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parallel metabolomics and lipidomics enables the comprehensive study of mouse brain regional metabolite and lipid patterns.
    Yu H; Villanueva N; Bittar T; Arsenault E; Labonté B; Huan T
    Anal Chim Acta; 2020 Nov; 1136():168-177. PubMed ID: 33081941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Web Server for Peak Detection, Baseline Correction, and Alignment in Two-Dimensional Gas Chromatography Mass Spectrometry-Based Metabolomics Data.
    Tian TF; Wang SY; Kuo TC; Tan CE; Chen GY; Kuo CH; Chen CS; Chan CC; Lin OA; Tseng YJ
    Anal Chem; 2016 Nov; 88(21):10395-10403. PubMed ID: 27673369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.